Product news from the 04/17/07 news brief

Share this article:
Eli Lilly has launched its first prescription drug for pets in the US, a beef-flavored chewable tablet that helps treat dogs for separation anxiety. The drug, marketed under the name Reconcile, uses the same compound as Lilly’s blockbuster antidepressant Prozac. Reconcile is designed to be used in combination with behavior management training to help dogs that have difficulty being separated from their owner or family members. Revenue projections and pricing for Reconcile were not made available. Reconcile has one competitor on the market Clomicalm, which is made my Novartis. GlaxoSmithKline received approval from the FDA to market Altabax, a new treatment for impetigo caused by strains of staphylococcus aureus or streptococcus pyogenes, the two most common types of bacteria in this skin infection that commonly affects children. Widespread use of antibiotics has led to bacteria becoming resistant to some drugs, creating a need for new treatments. Sepracor announced that Brovana brand (arformoterol tartrate) inhalation solution is now available by prescription in pharmacies nationwide. Brovana is a long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. The FDA approved Novartis’ Reclast (zoledronic acid), a treatment for patients with the bone condition Paget's disease. Paget's disease is estimated to affect about one million people in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.